Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,882
archived clinical trials in
Obesity Weight Loss

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Eugene, OR
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Beaver, PA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Beaver, PA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Pittsburgh, PA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
West Reading, PA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
West Reading, PA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Charleston, SC
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Greer, SC
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Bristol, TN
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
West Jordan, UT
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Arlington, VA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Arlington, VA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Henrico, VA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Henrico, VA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Virginia Beach, VA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Renton, WA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Wenatchee, WA
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Ciudad Autónoma de Bs As,
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Ciudad Autónoma de Bs As,
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Washington,
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated:  12/20/2017
Novo Nordisk Investigational Site
mi
from
Austin, TX
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Status: Enrolling
Updated: 12/20/2017
Novo Nordisk Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)
Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)
Status: Enrolling
Updated:  12/20/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)
Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)
Status: Enrolling
Updated: 12/20/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study
Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study
Status: Enrolling
Updated:  12/21/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study
Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study
Status: Enrolling
Updated: 12/21/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Antecedents of Obesity: Fetal Measures of Adiposity
Antecedents of Obesity: Fetal Measures of Adiposity, "A Plan for Obesity Disaster Management"
Status: Enrolling
Updated:  12/22/2017
University of Utah
mi
from
Salt Lake City, UT
Antecedents of Obesity: Fetal Measures of Adiposity
Antecedents of Obesity: Fetal Measures of Adiposity, "A Plan for Obesity Disaster Management"
Status: Enrolling
Updated: 12/22/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
Status: Enrolling
Updated:  12/27/2017
Stanford University School of Medicine
mi
from
Stanford, CA
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
Status: Enrolling
Updated: 12/27/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Status: Enrolling
Updated:  12/27/2017
Stanford University School of Medicine, Department of Anesthesia
mi
from
Stanford, CA
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Status: Enrolling
Updated: 12/27/2017
Stanford University School of Medicine, Department of Anesthesia
mi
from
Stanford, CA
Click here to add this to my saved trials
Improving High School Breakfast Environments
Improving High School Breakfast Environments
Status: Enrolling
Updated:  12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Improving High School Breakfast Environments
Improving High School Breakfast Environments
Status: Enrolling
Updated: 12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches
Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches
Status: Enrolling
Updated:  1/3/2018
Bald Eagle Middle/High School
mi
from
Wingate, PA
Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches
Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches
Status: Enrolling
Updated: 1/3/2018
Bald Eagle Middle/High School
mi
from
Wingate, PA
Click here to add this to my saved trials
Decision-Making and the Relationship to Food Intake in Kids
Understanding Decision-Making and the Relationship to Food Intake in Children 7 to 11 Years Old
Status: Enrolling
Updated:  1/3/2018
Pennsylvania State University
mi
from
University Park, PA
Decision-Making and the Relationship to Food Intake in Kids
Understanding Decision-Making and the Relationship to Food Intake in Children 7 to 11 Years Old
Status: Enrolling
Updated: 1/3/2018
Pennsylvania State University
mi
from
University Park, PA
Click here to add this to my saved trials
An Examination of a Weight Loss Formula on Health
An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk
Status: Enrolling
Updated:  1/3/2018
Exercise & Sport Nutrition Lab - Human Clinical Research Facility
mi
from
College Station, TX
An Examination of a Weight Loss Formula on Health
An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk
Status: Enrolling
Updated: 1/3/2018
Exercise & Sport Nutrition Lab - Human Clinical Research Facility
mi
from
College Station, TX
Click here to add this to my saved trials
Lifestyle Education for Activity and Nutrition for a Leaner You
Use of Electronic Feedback on Diet and Physical Activity to Enhance Weight Management
Status: Enrolling
Updated:  1/4/2018
University of South Carolina Department of Exercise Science
mi
from
Columbia, SC
Lifestyle Education for Activity and Nutrition for a Leaner You
Use of Electronic Feedback on Diet and Physical Activity to Enhance Weight Management
Status: Enrolling
Updated: 1/4/2018
University of South Carolina Department of Exercise Science
mi
from
Columbia, SC
Click here to add this to my saved trials
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates
Status: Enrolling
Updated:  1/4/2018
The Mayo Clinic
mi
from
Rochester, MN
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates
Status: Enrolling
Updated: 1/4/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Status: Enrolling
Updated:  1/5/2018
Novo Nordisk Investigational Site
mi
from
Tempe, AZ
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Status: Enrolling
Updated: 1/5/2018
Novo Nordisk Investigational Site
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Status: Enrolling
Updated:  1/5/2018
Novo Nordisk Investigational Site
mi
from
Lincoln, NE
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Status: Enrolling
Updated: 1/5/2018
Novo Nordisk Investigational Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory
Status: Enrolling
Updated:  1/9/2018
Bauer Family Resources (Head Start)
mi
from
Lafayette, IN
Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory
Status: Enrolling
Updated: 1/9/2018
Bauer Family Resources (Head Start)
mi
from
Lafayette, IN
Click here to add this to my saved trials
Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants
Early Life Exposure to Polycyclic Aromatic Hydrocarbons: Metabolic Perturbations and Epigenetic Biomarkers
Status: Enrolling
Updated:  1/10/2018
Montefiore Medical Center - Jack D. Weiler Division
mi
from
Bronx, NY
Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants
Early Life Exposure to Polycyclic Aromatic Hydrocarbons: Metabolic Perturbations and Epigenetic Biomarkers
Status: Enrolling
Updated: 1/10/2018
Montefiore Medical Center - Jack D. Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
Primary Care, Communication, and Improving Children's Health
Primary Care, Communication, and Improving Children's Health
Status: Enrolling
Updated:  1/10/2018
University of Texas Southwestern and Children's Medical Center
mi
from
Dallas, TX
Primary Care, Communication, and Improving Children's Health
Primary Care, Communication, and Improving Children's Health
Status: Enrolling
Updated: 1/10/2018
University of Texas Southwestern and Children's Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status
Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status
Status: Enrolling
Updated:  1/10/2018
University of Texas Southwestern and Children's Medical Center
mi
from
Dallas, TX
Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status
Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status
Status: Enrolling
Updated: 1/10/2018
University of Texas Southwestern and Children's Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Epigenetics and the Origin of Muscle Insulin Resistance in Humans
Epigenetics and the Origin of Muscle Insulin Resistance in Humans
Status: Enrolling
Updated:  1/11/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Epigenetics and the Origin of Muscle Insulin Resistance in Humans
Epigenetics and the Origin of Muscle Insulin Resistance in Humans
Status: Enrolling
Updated: 1/11/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.
School Wellness Policy: RCT to Implement & Evaluate Impact on Childhood Obesity
Status: Enrolling
Updated:  1/12/2018
Yale University
mi
from
New Haven, CT
Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.
School Wellness Policy: RCT to Implement & Evaluate Impact on Childhood Obesity
Status: Enrolling
Updated: 1/12/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women
Status: Enrolling
Updated:  1/12/2018
Northwestern University
mi
from
Chicago, IL
Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women
Status: Enrolling
Updated: 1/12/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
Status: Enrolling
Updated:  1/12/2018
John B. Pierce Laboratory
mi
from
New Haven, CT
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
Status: Enrolling
Updated: 1/12/2018
John B. Pierce Laboratory
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents
Study to Investigate Benefits of Weight Loss in Yound Adults and Adolescents
Status: Enrolling
Updated:  1/12/2018
Yale University
mi
from
New Haven, CT
Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents
Study to Investigate Benefits of Weight Loss in Yound Adults and Adolescents
Status: Enrolling
Updated: 1/12/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers
Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Status: Enrolling
Updated:  1/12/2018
Yale University School of Medicine Substance Abuse Treatment Unit
mi
from
New Haven, CT
Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers
Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Status: Enrolling
Updated: 1/12/2018
Yale University School of Medicine Substance Abuse Treatment Unit
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
Status: Enrolling
Updated:  1/16/2018
47 College Street
mi
from
New Haven, CT
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
Status: Enrolling
Updated: 1/16/2018
47 College Street
mi
from
New Haven, CT
Click here to add this to my saved trials
Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics
Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics (ALIVE-PD)
Status: Enrolling
Updated:  1/16/2018
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics
Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics (ALIVE-PD)
Status: Enrolling
Updated: 1/16/2018
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Status: Enrolling
Updated:  1/16/2018
Topeka VA Medical Center
mi
from
Topeka, KA
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Status: Enrolling
Updated: 1/16/2018
Topeka VA Medical Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Status: Enrolling
Updated:  1/16/2018
Kansas City VA Medical Center
mi
from
Kansas City, MO
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study
Status: Enrolling
Updated: 1/16/2018
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials